Pluri Inc. (PLUR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pluri Inc. (PLUR) has a cash flow conversion efficiency ratio of 0.565x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.21 Million) by net assets ($-9.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Pluri Inc. (PLUR) balance sheet quality index to measure how much of total assets are equity-financed.
Pluri Inc. - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Pluri Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Pluri Inc. to evaluate the quality of earnings relative to operating cash generation.
Pluri Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pluri Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Olympia Industries Bhd
KLSE:3018
|
0.024x |
|
Resource Development Group Ltd
AU:RDG
|
0.082x |
|
Simris Alg AB (publ)
ST:SIMRIS-B
|
-0.723x |
|
Kiriacoulis Mediterranean Cruises Shipping S.A.
AT:KYRI
|
N/A |
|
Sunlands Technology Group
NYSE:STG
|
0.151x |
|
United Maritime Corporation
NASDAQ:USEA
|
-0.012x |
|
N.C. Housing Public Company Limited
BK:NCH
|
0.024x |
|
Procorp S.A.B. de C.V
MX:PROCORPB
|
0.018x |
Annual Cash Flow Conversion Efficiency for Pluri Inc. (2002–2025)
The table below shows the annual cash flow conversion efficiency of Pluri Inc. from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see PLUR stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $-865.00K | $-18.21 Million | 21.053x | +732.61% |
| 2024-06-30 | $5.42 Million | $-18.02 Million | -3.328x | -122.77% |
| 2023-06-30 | $15.30 Million | $-22.86 Million | -1.494x | -31.73% |
| 2022-06-30 | $32.19 Million | $-36.50 Million | -1.134x | -109.68% |
| 2021-06-30 | $57.15 Million | $-30.91 Million | -0.541x | -15.07% |
| 2020-06-30 | $56.10 Million | $-26.37 Million | -0.470x | +65.18% |
| 2019-06-30 | $21.82 Million | $-29.45 Million | -1.350x | -79.97% |
| 2018-06-30 | $28.51 Million | $-21.38 Million | -0.750x | -4.98% |
| 2017-06-30 | $30.25 Million | $-21.61 Million | -0.714x | -47.17% |
| 2016-06-30 | $38.16 Million | $-18.52 Million | -0.485x | -36.98% |
| 2015-06-30 | $58.14 Million | $-20.61 Million | -0.354x | -15.14% |
| 2014-06-30 | $62.12 Million | $-19.12 Million | -0.308x | -4.74% |
| 2013-06-30 | $57.47 Million | $-16.89 Million | -0.294x | -238.65% |
| 2012-06-30 | $37.74 Million | $-3.27 Million | -0.087x | +34.53% |
| 2011-06-30 | $43.42 Million | $-5.75 Million | -0.133x | +90.24% |
| 2010-06-30 | $3.98 Million | $-5.41 Million | -1.358x | -8.18% |
| 2009-06-30 | $3.39 Million | $-4.26 Million | -1.256x | +35.54% |
| 2008-06-30 | $2.33 Million | $-4.54 Million | -1.948x | -274.03% |
| 2007-06-30 | $5.90 Million | $-3.07 Million | -0.521x | -116.39% |
| 2006-06-30 | $-644.23K | $-2.05 Million | 3.178x | +419.78% |
| 2005-06-30 | $1.80 Million | $-1.79 Million | -0.994x | +76.53% |
| 2004-06-30 | $357.01K | $-1.51 Million | -4.234x | -434.85% |
| 2003-06-30 | $490.42K | $-388.27K | -0.792x | -193.05% |
| 2002-06-30 | $-75.40K | $-64.16K | 0.851x | -- |
About Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD,… Read more